Scivita Medical Technology Co. Ltd. formed a long-term partnership with Boston Scientific Corp. to commercialize Scivita Medical's single-use percutaneous choledochoscope in China. This collaboration will increase the market penetration rate of the product.
Confo Therapeutics NV closed out March in much the same way as it began the month – with a deal. The Ghent, Belgium-based company has entered a collaboration agreement with Daiichi Sankyo Co. Ltd. to generate brain-penetrant small-molecule agonists to an undisclosed G protein-coupled receptor (GPCR) implicated in central nervous system diseases.
It’s been nearly 10 years since John Alam co-founded privately held EIP Pharma Inc. and the company’s upcoming merger with publicly traded Diffusion Pharmaceuticals Inc. will add scientific and financial muscle to its drive for a successful Lewy body treatment. To him, dealing with groundbreaking science requires patience.
The advance of antifungals – a class long needful of new therapies – continued with Scynexis Inc.’s potential $593 million exclusive license agreement with GSK plc for Brexafemme (ibrexafungerp), first cleared by the U.S. FDA in June 2021 and indicated for vulvovaginal candidiasis (VVC) as well as for reduction of recurrent VVC.
Biorchestra Co. Ltd. reached an exclusive research, option and licensing contract with a U.S.-based company to use its targeting technology platform to develop nucleic acid therapies to treat neurological disorders in a deal valued up to $861 million.
Junshi Biosciences Co. Ltd. and Rxilient Biotech Pte Ltd. are forming a joint venture (JV) to develop and commercialize Junshi’s PD-1 inhibitor, toripalimab, in nine Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.
Boehringer Ingelheim GmbH has agreed to pay Covant Therapeutics Inc. $10 million for exclusive rights to the latter’s ADAR1-targeting immuno-oncology program. Under the terms of the exclusive research collaboration and worldwide licensing agreement, newly unveiled drug discovery company Covant will carry out the preclinical work in creating an ADAR1 small-molecule inhibitor, with Boehringer offering its scientific expertise to help advance the program into the clinic.
Biohaven Ltd. has acquired global rights, excluding China, from Highlightll Pharmaceutical Co. Ltd. to develop and commercialize a dual inhibitor of tyrosine kinase 2 (TYK2) and JAK1, BHV-8000 (TLL-041), for the treatment of brain disorders in a deal worth up to $970 million.
The increased availability of capital, greater access to talent, strong local governmental support and more focused attention on IP issues have increased the complexity of deals taking place between biotech and big pharma companies in China, according to Michelle Chan, chief business officer of Insilico Medicine Inc.
Triastek Inc., a digital pharmaceutical solutions company, is taking a unique approach by using 3D printing technology to develop a pipeline that spans rheumatoid arthritis (RA), clotting disorders, ulcerative colitis and pulmonary hypertension. Its technology was recently validated through a partnership with Boehringer Ingelheim GmbH. The company’s 3D printing products include T-19, T-20 and T-21, which have all received IND approval from the FDA.
RSS
